Jazz Pharmaceuticals signs multimillion-dollar deal for experimental cancer therapy
July 10, 2019 at 11:57 AM EDT
Jazz is paying $3.5 million up front, and another $203 million in contingent payments tied to hitting product development milestones, for an England company's cancer therapy program.
